Novartis Pediatric Triaminic Target Of Proposed Class Action
This article was originally published in The Tan Sheet
Executive Summary
Novartis' Triaminic Daytime Cold & Cough, one of the OTC children's cold product lines voluntarily withdrawn from the market in 2007 due to concerns about misuse, is the subject of proposed class action
You may also be interested in...
Pre-emption Among Legal Hurdles For Triaminic Proposed Class Action
A proposed class action alleging Novartis marketed pediatric cough/cold products that were ineffective and unsafe likely faces an uphill battle, according to industry attorneys including former FDA Chief Counsel Peter Barton Hutt
Pre-emption Among Legal Hurdles For Triaminic Proposed Class Action
A proposed class action alleging Novartis marketed pediatric cough/cold products that were ineffective and unsafe likely faces an uphill battle, according to industry attorneys including former FDA Chief Counsel Peter Barton Hutt
Pre-emption Among Legal Hurdles For Triaminic Proposed Class Action
A proposed class action alleging Novartis marketed pediatric cough/cold products that were ineffective and unsafe likely faces an uphill battle, according to industry attorneys including former FDA Chief Counsel Peter Barton Hutt